Skip Navigation


NDT Advance Access originally published online on August 2, 2005
Nephrology Dialysis Transplantation 2005 20(11):2315-2317; doi:10.1093/ndt/gfi046
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
20/11/2315    most recent
gfi046v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Boudville, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Boudville, N.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2005]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Editorial Comment

The predictable effect that renal failure has on H2 receptor antagonists—increasing the half-life along with increasing prescribing errors

Neil Boudville

Sir Charles Gairdner Hospital, School of Medicine and Pharmacology, University of Western Australia, Australia

Correspondence and offprint requests to: Dr Neil Boudville, University of Western Australia, Sir Charles Gairdner Hospital, School of Medicine and Pharmacology, 4th Floor G Block, Verdun Street Nedlands, WA Australia 6009. Email: nboudvil@cyllene.uwa.edu.au

Keywords: histamine H2 antagonists; kidney failure; kidney failure, acute; kidney failure, chronic; medication errors; pharmocokinetics

The first 10% of the full text of this article appears below.



   Introduction
 
In this edition of NDT, Manlucu et al. [1] present results from a systematic review they performed on dose reducing of histamine 2 receptor antagonists (H2RA) in the presence of renal failure. Fundamentally, they demonstrate that H2RA should be given in lower doses as renal function deteriorates. These results in themselves are not surprising as H2RA are primarily excreted in the urine unchanged, and there is substantial evidence that clearance is reduced with renal failure [2–4]. The more surprising result is that these authors managed to identify 16 published clinical . . . [Full Text of this Article]



   Methods to overcome preventable adverse drug events
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?